Myeloid Resistance is not Futile: Biomarkers of Immunotherapy in Bladder Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34045294.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The majority of patients with urothelial cancer do not respond to immune checkpoint blockade directed at the PD-(L)1 axis. Recently, robust profiling data were used to derive predictive biomarker signatures for both protumorigenic immunity and adaptive antitumor immunity; combining these has greater predictive power than either alone. Clinically, these results suggest that myeloid cells may be primary drivers of nonresponsiveness in urothelial cancer.<i>See related article by Wang et al., p. 4287</i>.
Medical subject headings
- Biomarkers, Tumor
- Carcinoma, Transitional Cell
- Drug Resistance, Neoplasm
- Immunotherapy
- Myeloid Cells
- Urinary Bladder Neoplasms